SSSohel Somani

Sohel Somani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sohel Somani has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Eye Care Needs and Barriers Among Patients Attending a Hospital in Najaf, Iraq: A Cross-Sectional Survey

    by Mayar Alkhawaja, Khaldon Abbas, Hasan H Al-Hakim, Mustafa E Alnajm, Hawraa Jawad Alrufaye, Tuqa Hayder Al-Kilabi, Hussein Dhiban, Aya A Al-Waeli, Ayat R Al-Ardawi, Layth Raad Mahboba, et al.

    Introduction: This hospital-based survey aimed to elucidate the demographic, socioeconomic, and geographic factors associated with vision issues and eye care barriers among patients in Najaf, Iraq. Materials and Methods: Participants presenting to Al-Sajjad Hospital were recruited through convenience sampling from July 3, 2025 to September 20, 2025. Bivariate associations between demographic/social factors and self-reported vision problems/care access were assessed using chi-square tests. Multivariable logistic regression identified factors associated with unmet care needs. Results: In total, 213 participants were enrolled. Among respondents, 35.1% reported a monthly household income of 250,000-500000 Iraqi dinars (IQD) (~191-382 United States Dollar [USD]). Among reported ocular concerns, blurred vision (70.8%), eye pain (55.1%), and redness/discharge (49.7%) were the most frequent. Among participants citing inaccessibility to eye care within the previous year (44.2%), respondents could select more than one barrier: financial constraints (83.5%), lack of nearby clinics (16.5%), and long wait-times (14.3%) were the most commonly reported. On multivariable analysis, older age (≥ 31 years, across all three age categories examined) and longer travel distance were significantly independently associated with unmet care needs, with the largest point estimates observed for the oldest age group (> 60 years: OR=4.98, 95% CI=1.66-16.08, p=0.005) and the furthest travel-distance category (> 20 km: OR=4.24, 95% CI=1.42-14.08, p=0.013). Discussion: Survey respondents reported high burden of ocular symptoms alongside low corrective lens uptake. Financial constraints, older age, and longer travel distance emerged as key barriers, while near-universal willingness to attend free local screenings supports the development of community-informed initiatives. Conclusions: Older age and greater travel distance to clinics were associated with unmet eye care needs. This highlights the importance of locally tailored interventions to improve equitable access to eye care services in underserved Iraqi communities.

  • Periorbital Fat Atrophy With Topical Bimatoprost in Glaucoma, Ocular Hypertension, and Cosmetic Use: Systematic Review and Meta-Analysis

    by Laila Sheather, Zeena Kailani, Aljeena Rahat Qureshi, Zaynab Somani, Sangsu Han, Sohel Somani

    Purpose: To synthesize evidence on bimatoprost-associated periorbital fat atrophy, compare outcomes across prostaglandin analogues, and evaluate reversibility after discontinuation. Methods: PubMed, Embase, Web of Science, and the Cochrane Library were systematically searched from inception to August 2025 according to an a priori protocol (International Prospective Register of Systematic Reviews CRD420251107027). Studies evaluating periorbital structural changes in human subjects using topical bimatoprost for glaucoma, ocular hypertension, or cosmetic indications were included. Risk of bias was assessed using Joanna Briggs Institute tools. Random-effects meta-analyses estimated risk ratios comparing bimatoprost with latanoprost and travoprost for deepening of the upper eyelid sulcus, periorbital fat loss, enophthalmos, and dermatochalasis involution. Results: Forty-five studies comprising 7,106 participants (3,176 bimatoprost-exposed) were included. Meta-analysis of five comparative studies (742 eyes) demonstrated a significantly higher risk of deepening of the upper eyelid sulcus (risk ratio, 2.92 [95% CI, 1.98–4.30]; Grading of Recommendations Assessment, Development, and Evaluation = low) and periorbital fat loss (risk ratio, 3.10 [95% CI, 1.07–8.99]; Grading of Recommendations Assessment, Development, and Evaluation = very low) with bimatoprost versus latanoprost. No significant differences were observed between bimatoprost and travoprost for any outcome (Grading of Recommendations Assessment, Development, and Evaluation = very low). Reversibility was variable; deepening of the upper eyelid sulcus showed the greatest resistance to recovery. Conclusions: Bimatoprost carries a significantly elevated risk of periorbital fat atrophy compared with latanoprost, with nearly three-fold increased risk; however, the certainty of evidence is low to very low. Bimatoprost and travoprost demonstrate equivalent periorbital adverse effect profiles, suggesting that switching between them is unlikely to reduce periorbital effects. These findings support the preferential use of latanoprost when periorbital appearance is a priority. Limitations include heterogeneity in outcome assessment and predominance of observational designs.

  • Open Access

    Comparative Visual Outcomes and Complications of Light Adjustable Intraocular Lens Technology: A Scoping Review

    by Anita B Chander, Eric Tam, Sohel Somani

    Purpose: A scoping review was completed to evaluate visual outcomes of the light adjustable lens (LAL) relative to alternative intraocular lenses (IOLs) and post-operative adverse events associated with the LAL. Methods: A structured search of MEDLINE, EMBASE, and CENTRAL was completed to identify primary studies of cataract surgery with LAL implantation. Results: Twenty studies (1743 eyes) were included. Six studies (30%) compared the visual performance of LAL to another IOL, reporting sphere (n = 2 studies), spherical equivalent (SE; n = 5), and residual cylinder (n = 6). Residual cylinder was lower with the LAL across all 6 studies, whereas comparative SE outcomes were variable. Uncorrected visual acuity (UCVA) was reported in 4 studies, with all 4 studies demonstrating improved UCVA with the LAL. Adverse events were reported in 18 studies (90%). Posterior capsular opacification or YAG capsulotomy was reported in the largest number of studies (n = 8 studies), with study-level proportions ranging from 0.7% to 28.6% of eyes. Macular edema was reported in 6 studies (0.6% to 10.9% of eyes) and secondary surgical interventions in 5 studies (1.0% to 12.5% of eyes). The first light delivery device (LDD) treatment was performed 17 to 24 days after surgery in 7 studies (35%). Conclusion: LAL technology is associated with reduced residual refractive cylinder and improved UCVA compared to monofocal IOLs. The small number of comparative studies and heterogeneity across sources limit the strength of this evidence. The potential for UV light contamination with first generation models and LDD treatment delays warrant consideration.

  • Newcomers to the North: barriers to eyecare for new adult immigrants to Northern Ontario

    by Arjav Gupta, Chris Francis, Leland Dhurjon, Sanjoy Gupta, Lili Tong, Eric Tam, Fariba Nazemi, Sohel Somani

  • Open Access

    Social Determinants of Health and Barriers in Accessing Eye Care for Refugees in the Greater Toronto Area

    by Mohammed Abbas, Khaldon F Abbas, Mariam Issa, Eric S Tam, Sohel Somani

    Purpose: To evaluate ocular health status, vision-related quality of life, and access to eye care services among a multi-ethnic refugee population in the Greater Toronto Area (GTA). Methods: Participants completed a structured survey capturing demographic, medical, and vision-related data. Descriptive statistics were employed to summarize and interpret the responses. Canadian population data were sourced from Statistics Canada and National Vision Health Reports. Participants were recruited during ophthalmic screening outreach visits at four refugee housing sites in the GTA, and were eligible if they were adults or mature minors residing in refugee homes after arriving in Canada as refugees or asylum seekers between October 2022 and October 2024. Proportions were converted to estimated counts for comparison, and harmonized categorical variables were analyzed using Pearson’s Chi-Square or Fisher’s Exact Test. Bivariate and multivariate logistic regression models were then used to assess associations between demographic, clinical, and psychosocial factors and two outcomes: difficulty coping with life due to vision and history of barriers to eye care. Results: Among 94 refugee participants (mean age 46.5 years; 41% female), rates of recent eye exams (19.1%) and prescription glasses use (51.1%) were significantly lower than in the Canadian population (74.5% and 81.0%, respectively; p< 0.0001). Over half (55.3%) were dissatisfied with their vision, and financial barriers (50%) were the most reported obstacle to care. Prior abuse was associated with greater odds of encountering barriers (OR=7.65, p=0.005), while dissatisfaction with vision (OR=0.11, p=0.025) and interference with daily activities (OR=233.0, p< 0.0001) strongly predicted difficulty coping. Conclusion: Refugees face significant vision-related health disparities. Interventions should address access, government benefits, education, and psychosocial supports.


  • Open Access

    Comparative outcomes of aflibercept biosimilars and reference aflibercept in nAMD: a systematic review and meta-analysis

    by Korolos Sawires, Harrish Nithianandan, Sohel Somani

    Objective: To evaluate the literature-pooled functional, anatomical and safety outcomes of aflibercept biosimilars compared with reference aflibercept for neovascular age-related macular degeneration (nAMD). Methods and analysis: Systematic review and meta-analysis. Medline, Embase and CENTRAL were searched from inception to 2 June 2025. Phase 3 randomised controlled trials (RCTs) comparing aflibercept biosimilars with the reference product in patients with nAMD were included. Two independent reviewers conducted screening, data extraction, risk of bias (RoB 2) assessment and certainty of evidence assessment (Grading of Recommendations, Assessment, Development and Evaluation), with a third reviewer resolving discrepancies. Primary outcomes included mean difference (MD) change in best-corrected visual acuity (BCVA) and retinal thickness over time, risk ratio (RR) for proportion of participants gaining >15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters and RR for adverse events. Meta-regression was used to evaluate the temporal stability of continuous outcomes. Results: Six RCTs involving 2044 participants (1026 biosimilar, 1018 reference) were included. Five aflibercept biosimilars were evaluated, representing more than 50% of the eight biosimilars currently approved worldwide. Meta-regression revealed no significant difference in MD change in BCVA over time between biosimilar and reference aflibercept (slope: 0.0321 letters/week; p=0.1013). For MD change in retinal thickness, an initial anatomical advantage for reference aflibercept at week 0 (intercept: 9.58 µm; p=0.0449) was not sustained over time (slope: –0.1685 µm/week; p=0.2303). The pooled RR for gaining >15 ETDRS letters from baseline was 1.19 (95% CI 0.98 to 1.45; p=0.079). No statistically significant differences were observed across 15 safety outcomes. Conclusion: This systematic review and meta-analysis found no statistically significant differences in functional, anatomical or safety outcomes between aflibercept biosimilars and the reference product for nAMD, based on moderate to high certainty evidence. Functional and anatomical outcomes appeared stable across multiple timepoints. Further long-term pharmacovigilance studies and real-world data beyond 56 weeks are warranted. PROSPERO registration number: CRD420251048633.


  • Cost analysis of immediate versus delayed bilateral cataract surgery in seniors in community-based ambulatory surgical centers in a post-COVID-19 era

    by Francesca Lee, Zaynab Somani, Eric S. Tam, Hannah H Chiu, Lili Tong, Steve Arshinoff, Sohel Somani

  • Health care utilization, prevalence, and risk factors of dry eyes after cataract surgery

    by Saffire H. Krance, Amin Hatamnejad, Rutmila Uddin, Sohel Somani, Eric Tam, Fahmeeda Murtaza, Hannah H. Chiu


  • Reply: Anterior chamber cytokine production and postoperative macular edema in patients with diabetes undergoing FLACS

    by Milena Bhsc Cioana, Sohel Md Frcsc Somani

    An abstract is unavailable. This article is available as a PDF only.